The encouraging results of the LUMINA trial support the safe omission of adjuvant radiation following breast-conserving surgery when selection criteria are strictly limited to low-risk cancers (T1N0, grade 1 or 2) with luminal A phenotype with a Ki-67 index of ≤ 13.25%. Here, MKI67 is linked to cancer.